IN2009KN04355A - - Google Patents
Download PDFInfo
- Publication number
- IN2009KN04355A IN2009KN04355A IN4355KON2009A IN2009KN04355A IN 2009KN04355 A IN2009KN04355 A IN 2009KN04355A IN 4355KON2009 A IN4355KON2009 A IN 4355KON2009A IN 2009KN04355 A IN2009KN04355 A IN 2009KN04355A
- Authority
- IN
- India
- Prior art keywords
- promoter
- poll
- useful
- rna polymerase
- rna
- Prior art date
Links
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 102000017143 RNA Polymerase I Human genes 0.000 abstract 1
- 108010013845 RNA Polymerase I Proteins 0.000 abstract 1
- 108020000999 Viral RNA Proteins 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000008488 polyadenylation Effects 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94665107P | 2007-06-27 | 2007-06-27 | |
| EP07450177A EP2045323A1 (en) | 2007-10-05 | 2007-10-05 | Linear expression constructs for production of influenza virus particles |
| PCT/EP2008/058182 WO2009000891A2 (en) | 2007-06-27 | 2008-06-26 | Linear expression constructs for production of influenza virus particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2009KN04355A true IN2009KN04355A (enExample) | 2015-07-10 |
Family
ID=39099653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4355KON2009 IN2009KN04355A (enExample) | 2007-06-27 | 2008-06-26 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100129399A1 (enExample) |
| EP (2) | EP2045323A1 (enExample) |
| CN (1) | CN101952427A (enExample) |
| AU (1) | AU2008267180B2 (enExample) |
| CA (1) | CA2689569C (enExample) |
| EA (1) | EA017456B1 (enExample) |
| IN (1) | IN2009KN04355A (enExample) |
| NZ (1) | NZ582102A (enExample) |
| WO (1) | WO2009000891A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9091510B2 (en) | 2007-03-21 | 2015-07-28 | Schott Corporation | Transparent armor system and method of manufacture |
| EP2072058A1 (en) | 2007-12-21 | 2009-06-24 | Avir Green Hills Biotechnology Research Development Trade Ag | Modified influenza virus |
| EP2233568A1 (en) | 2009-03-19 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade AG | Novel method for generation of RNA virus |
| JP5836266B2 (ja) | 2009-05-21 | 2015-12-24 | ノバルティス アーゲー | 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学 |
| WO2011012999A1 (en) * | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| KR20120083480A (ko) | 2009-10-20 | 2012-07-25 | 노파르티스 아게 | 바이러스 구제를 위한 개선된 역유전학 방법 |
| EP2576773A2 (en) * | 2010-06-02 | 2013-04-10 | Avir Green Hills Biotechnology Research Development Trade AG | Methods and helper viruses for the generation of rna virus |
| CN102495208B (zh) * | 2011-10-24 | 2014-03-26 | 山东省农业科学院畜牧兽医研究所 | 禽流感病毒rt-pcr elisa试剂盒 |
| US10206997B2 (en) * | 2011-11-10 | 2019-02-19 | Bin Wang | Facilitator-DNA combination vaccine |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| US9708585B2 (en) | 2012-12-03 | 2017-07-18 | Seqirus UK Limited | Influenza virus reassortment |
| CA2905612A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| CN105722976A (zh) | 2013-06-06 | 2016-06-29 | 诺华股份有限公司 | 流感病毒重配 |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK288544B6 (sk) * | 1998-06-12 | 2018-03-05 | Mount Sinai School Of Medicine | Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie |
| DE69937999T2 (de) * | 1998-06-12 | 2009-01-29 | Avir Green Hills Biotechnology Research Development Trade Ag | Interferon induzierende genetisch veränderte attenuierte viren |
| WO2000056914A1 (en) * | 1999-03-24 | 2000-09-28 | Gene Therapy Systems, Inc. | Method for generating transcriptionally active dna fragments |
| DK1820853T3 (da) * | 1999-04-06 | 2011-12-19 | Wisconsin Alumni Res Found | Rekombinant influenzavirus til vacciner og genterapi |
| DE122007000070I1 (de) * | 1999-07-14 | 2008-01-31 | Sinai School Medicine | In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren |
| AU5921101A (en) * | 2000-04-28 | 2001-11-12 | St Jude Childrens Res Hospital | Dna transfection system for the generation of infectious influenza virus |
| CN1678345B (zh) * | 2002-04-26 | 2013-09-11 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| EP1697521B1 (en) * | 2003-12-23 | 2010-06-02 | MedImmune, LLC | Multi plasmid system for the production of influenza virus |
| BRPI0511776B1 (pt) * | 2004-06-01 | 2016-11-29 | Sinai School Medicine | vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica |
| CN101103103A (zh) * | 2004-11-19 | 2008-01-09 | 威斯康星旧生研究基金会 | 具有串联转录单位的重组流感病毒载体 |
| US8043856B2 (en) * | 2007-06-14 | 2011-10-25 | Wisconsin Alumni Research Foundation | Adenoviral vectors for influenza virus production |
-
2007
- 2007-10-05 EP EP07450177A patent/EP2045323A1/en not_active Withdrawn
-
2008
- 2008-06-26 EA EA201000076A patent/EA017456B1/ru not_active IP Right Cessation
- 2008-06-26 US US12/666,459 patent/US20100129399A1/en not_active Abandoned
- 2008-06-26 NZ NZ582102A patent/NZ582102A/en not_active IP Right Cessation
- 2008-06-26 WO PCT/EP2008/058182 patent/WO2009000891A2/en not_active Ceased
- 2008-06-26 CN CN2008800223549A patent/CN101952427A/zh active Pending
- 2008-06-26 CA CA2689569A patent/CA2689569C/en active Active
- 2008-06-26 EP EP08774359.7A patent/EP2160462B1/en active Active
- 2008-06-26 AU AU2008267180A patent/AU2008267180B2/en active Active
- 2008-06-26 IN IN4355KON2009 patent/IN2009KN04355A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008267180B2 (en) | 2014-07-10 |
| US20100129399A1 (en) | 2010-05-27 |
| WO2009000891A2 (en) | 2008-12-31 |
| NZ582102A (en) | 2012-06-29 |
| WO2009000891A3 (en) | 2009-02-26 |
| EP2045323A1 (en) | 2009-04-08 |
| AU2008267180A1 (en) | 2008-12-31 |
| EA017456B1 (ru) | 2012-12-28 |
| EP2160462A2 (en) | 2010-03-10 |
| CA2689569C (en) | 2020-10-27 |
| CA2689569A1 (en) | 2008-12-31 |
| EP2160462B1 (en) | 2017-07-26 |
| EA201000076A1 (ru) | 2010-06-30 |
| CN101952427A (zh) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009000891A3 (en) | Linear expression constructs for production of influenza virus particles | |
| EA200501890A1 (ru) | Вирусы гриппа высокого титра для приготовления вакцин и генной терапии | |
| MXPA06013411A (es) | Procedimiento para la produccion de una vacuna contra la influenza. | |
| EP3492597A3 (en) | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer | |
| NZ606087A (en) | Influenza vaccine | |
| TR201815882T4 (tr) | Tal efektörü aracılı dna modifikasyonu. | |
| MX2018008135A (es) | Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas. | |
| EP4349405A3 (en) | Respiratory virus vaccines | |
| MX2016002586A (es) | Métodos y composiciones para el tratamiento guiado por rna de infección por hiv. | |
| WO2007053696A3 (en) | Rnai inhibition of influenza virus replication | |
| WO2009080806A3 (en) | Modified influenza virus | |
| EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
| AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
| EP4126032A4 (en) | Universal influenza vaccine using nucleoside-modifield mrna | |
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| GB2386072A (en) | Novel vaccine | |
| NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| AU2024235086A1 (en) | Nucleic acid influenza vaccines and respiratory virus combination vaccines | |
| GEP20115293B (en) | Isolated extract of walnuts, process for its obtaining and its use | |
| NZ597601A (en) | Treatment and prevention of influenza | |
| GB201303867D0 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| MA35034B1 (fr) | Procedes de preparation de pepsipeptides macrocycliques et nouveaux intermediaires | |
| MX343948B (es) | Compuestos de peroxido organico para inactivacion de microorganismos. | |
| WO2012058493A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
| EA201100902A1 (ru) | Новый способ получения рнк-вируса |